Personalized Medicine Leverage Interpace’s core focus on personalized medicine, including molecular diagnostics, bioinformatics, and pharmacogenomics, to position expanded diagnostic panels and companion diagnostics partnerships with pharma and biotechs seeking risk stratification and targeted therapies.

Diagnostics Expansion Target opportunities around Interpace Diagnostics Pleural Biopsy System and thyroid cancer test platforms (ThyGeNEXT and miRNA risk classifiers) for hospitals and outpatient centers looking to enhance minimally invasive cancer diagnostics and clinical decision support.

Pharmacogenomics Offer pharmacogenomics and genotyping services to pharmaceutical and biotech sponsors for patient stratification in clinical trials, as well as real-world evidence programs to improve drug safety profiles and trial success rates.

Strategic Partnerships Explore collaboration with biotech players and academic partners highlighted by past ties to Twist Bioscience and Genecast, presenting a pathway for translational studies, co-development of biomarkers, and joint development of diagnostic/therapeutic solutions.

Growth Funding & Scale With a revenue base of up to 50M and a 70M funding runway, position Interpace as an agile partner for scalable service delivery, bioinformatics infrastructure, and data solutions to support expanding clinical programs and international expansion.